论文部分内容阅读
星形孢菌素(STS)是一种作用很强的抗癌物质,但是30年来,由于STS在血液中不稳定,且其不具选择性,在杀死癌症细胞的同时会杀死正常细胞等问题,STS一直无法用于临床。日前,美国加州大学圣地亚哥医学院的研究人员提供了一个有效解决上述问题的途径,相关的研究结果发表在2013年10月20日的《International Journal of Nanomedicine》上。1977年,科学家从链霉菌staurosporeus分离出STS,STS能够促使多种类型的癌症细胞凋亡。研究发现,STS能够特异地干扰多个细胞信号通道,甚至能有效杀灭对前线抗癌化疗药物无效的癌细胞株。因此,STS对治疗耐
Staurosporine (STS) is a potent anti-cancer substance, but for 30 years STS has been shown to kill cancer cells and kill normal cells, as STS is unstable in the bloodstream and is not selective Problem, STS has not been available for clinical use. Recently, researchers at the University of California, San Diego Medical School provided an effective solution to the above problems. Relevant findings were published in the October 20, 2013, International Journal of Nanomedicine. In 1977, scientists isolated STS from Streptomyces staurosporeus, an enzyme that STS can promote in many types of cancer cells. The study found that STS can specifically interfere with multiple cell signaling pathways, and can even effectively kill cancer cell lines that are ineffective with frontline anticancer chemotherapy drugs. Therefore, STS is resistant to treatment